| Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study FJ de Abajo, S Rodríguez-Martín, V Lerma, G Mejía-Abril, M Aguilar, ... The Lancet 395 (10238), 1705-1714, 2020 | 486 | 2020 |
| Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates M Saiz-Rodríguez, S Almenara, M Navares-Gómez, D Ochoa, M Román, ... Biomedicines 8 (4), 94, 2020 | 78 | 2020 |
| Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants M Saiz‐Rodríguez, C Belmonte, M Román, D Ochoa, C Jiang‐Zheng, ... Basic & Clinical Pharmacology & Toxicology 123 (4), 474-485, 2018 | 70 | 2018 |
| Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects M Saiz‐Rodríguez, D Ochoa, C Herrador, C Belmonte, M Román, E Alday, ... Basic & clinical pharmacology & toxicology 124 (3), 321-329, 2019 | 63 | 2019 |
| Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to … D Koller, V Vaitsekhovich, C Mba, JL Steegmann, P Zubiaur, ... Talanta 208, 120450, 2020 | 58 | 2020 |
| Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase … D Koller, P Zubiaur, M Saiz-Rodríguez, F Abad-Santos, A Wojnicz Talanta 198, 159-168, 2019 | 45 | 2019 |
| Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis M García-Ferrer, A Wojnicz, G Mejía, D Koller, P Zubiaur, F Abad-Santos Clinical Therapeutics 41 (12), 2558-2570. e7, 2019 | 42 | 2019 |
| Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics M Saiz-Rodríguez, D Ochoa, C Belmonte, M Román, D Vieira de Lara, ... Journal of Psychopharmacology 33 (4), 522-531, 2019 | 42 | 2019 |
| Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone P Soria-Chacartegui, G Villapalos-García, P Zubiaur, F Abad-Santos, ... Frontiers in Pharmacology 12, 711940, 2021 | 33 | 2021 |
| Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics D Koller, S Almenara, G Mejía, M Saiz-Rodríguez, P Zubiaur, M Román, ... Advances in therapy 38, 1035-1054, 2021 | 30 | 2021 |
| Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention M Saiz-Rodríguez, C Belmonte, JL Caniego, D Koller, P Zubiaur, ... Clinical Therapeutics 41 (6), 1199-1212. e2, 2019 | 30 | 2019 |
| SLCO1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability P Zubiaur, MD Benedicto, G Villapalos-García, M Navares-Gómez, ... Journal of Personalized Medicine 11 (3), 204, 2021 | 26 | 2021 |
| The effects of Aripiprazole and olanzapine on pupillary light reflex and its relationship with Pharmacogenetics in a randomized Multiple‐Dose trial D Koller, M Saiz‐Rodríguez, P Zubiaur, D Ochoa, S Almenara, M Román, ... British journal of clinical pharmacology 86 (10), 2051-2062, 2020 | 25 | 2020 |
| Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran P Zubiaur, M Saiz-Rodríguez, D Ochoa, M Navares-Gómez, G Mejía, ... Advances in Therapy 37 (8), 3537-3550, 2020 | 22 | 2020 |
| Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers P Zubiaur, P Soria-Chacartegui, D Koller, M Navares-Gómez, D Ochoa, ... Biomedicine & Pharmacotherapy 133, 111087, 2021 | 21 | 2021 |
| Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers D Koller, C Belmonte, M Saiz‐Rodríguez, P Zubiaur, M Román, D Ochoa, ... Basic & clinical pharmacology & toxicology 126 (3), 236-246, 2020 | 16 | 2020 |
| The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice D Grajales, P Vázquez, M Ruíz-Rosario, E Tudurí, M Mirasierra, V Ferreira, ... Diabetologia, 1-16, 2022 | 15 | 2022 |
| Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach LA Kneller, P Zubiaur, D Koller, F Abad-Santos, G Hempel Clinical Pharmacokinetics 60 (12), 1569-1582, 2021 | 15 | 2021 |
| PriME-PGx: La Princesa University Hospital multidisciplinary initiative for the implementation of pharmacogenetics P Zubiaur, G Mejía-Abril, M Navares-Gómez, G Villapalos-García, ... Journal of Clinical Medicine 10 (17), 3772, 2021 | 15 | 2021 |
| Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects D Koller, C Belmonte, R Lubomirov, M Saiz-Rodríguez, P Zubiaur, ... Journal of psychopharmacology 32 (11), 1212-1222, 2018 | 15 | 2018 |
